Healthcare
Technology
Health

Horizon Therapeutics

$25.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.23 (0.93%) Today
+$0.35 (1.41%) After Hours

Why Robinhood?

You can buy or sell HZNP and other stocks, options, ETFs, and crypto commission-free!

About

Horizon Therapeutics Public Limited Company Ordinary Shares, also called Horizon Therapeutics, is a biopharmaceutical company which is engaged in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. Read More It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Employees
1,000
Headquarters
Dublin, Dublin
Founded
2008
Market Cap
4.59B
Price-Earnings Ratio
94.27
Dividend Yield
0.00
Average Volume
1.69M
High Today
$25.34
Low Today
$24.66
Open Price
$24.66
Volume
646.51K
52 Week High
$29.44
52 Week Low
$15.75

Collections

Healthcare
Technology
Health
Pharmaceutical
Therapy
Biopharmaceutical
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 16

Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout

DUBLIN--(BUSINESS WIRE)-- -- Research that has redefined the trajectory and true impact of the disease underscores the campaign -- Horizon Therapeutics plc (HZNP) today announced the launch of Gout Lies, a data-driven campaign to reframe physician dialogue on the reality of living with gout and underscore findings of recent research that warrant a new view on how to properly manage the disease. Scroll to continue with content Ad Through a mix of thought-provoking visuals, expert videos and clinical data...

53
Yahoo FinanceMay 9

Horizon Therapeutics' Q1 Earnings Beat Estimates

Horizon Therapeutics plc HZNP, previously known as Horizon Pharma plc, reported first-quarter adjusted earnings of 30 cents per share, which beat the Zacks Consensus Estimate of 10 cents and increased from 3 cents reported in the year-ago quarter.

44
Yahoo FinanceMay 8

Here's How Horizon Therapeutics Blew Past Wall Street Estimates in Q1

The last time Horizon Therapeutics (NASDAQ: HZNP), formerly known as Horizon Pharmaceuticals, announced its quarterly results, investors were treated to some very good news.

19

Earnings

$0.03
$0.24
$0.46
$0.67
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.